CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SMARTdrugs aims to develop innovative cancer therapies by utilizing supramolecular chemistry to create radiotheranostics, which combine diagnostic and therapeutic functions in a single compound. The project focuses on enhancing drug delivery to lung and brain cancers through non-covalent systems.
From diagnostic applications in the quantification and characterisation of biomarker expression in cancer patients, through to molecularly targeted radionuclide therapy, radiopharmaceuticals are at the frontline of modern personalised medicine.
The radical long-term vision of SMARTdrugs is to harness the untapped potential of supramolecular chemistry to create a new class of therapies - radiotheranostics - which combine both diagnostic and therapeutic radionuclides in one compound.
By using the…
TECHNISCHE UNIVERSITAET MUENCHEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Utrecht
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, San Sebastian
Type: Research institute
Activity type: Research Organisations
SME: No
Switzerland, Zurich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
